With the use of HEDERA DX's liquid biopsy solution, hospital labs will be able to conduct clinically useful liquid biopsies on their own. This will greatly simplify tumor profiling. It is difficult to accomplish IVD compliance, privacy infrastructure, and validation, and even if these challenges are overcome, the current software workflows are inefficient to use and lack key capabilities. HEDERA DX was established on July 1, 2021, in Epalinges, Vaud.